Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder

被引:33
作者
Ferris, Craig F. [1 ]
Rasmussen, Mads F. [2 ]
Messenger, Tara [1 ]
Koppel, Gary [3 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Psychiat, Program Behav Neurosci, Worcester, MA 01655 USA
[2] Univ Copenhagen, Lab Neuropsychiat, Copenhagen, Denmark
[3] Butler Univ, Dept Chem, Indianapolis, IN 46208 USA
关键词
D O I
10.1186/1471-2202-2-10
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Alterations in arginine vasopressin regulation and secretion have been proposed as one possible biochemical abnormality in patients with obsessive-compulsive disorder. In golden hamsters, arginine vasopressin microinjections into the anterior hypothalamus trigger robust grooming and flank marking, a stereotyped scent marking behaviors. The intensity and repetition of the behaviors induced by arginine vasopressin is somewhat reminiscent of Obsessive Compulsive Disorder in humans. The present experiments were carried out to test whether pharmacological agents used to alleviate obsessive compulsive disorder could inhibit arginine vasopressin-induced flank marking and grooming. Results: Male golden hamsters were treated daily for two weeks with either vehicle, fluoxetine, clomipramine, or desipramine (an ineffective drug), before being tested for arginine vasopressin-induced flank marking and grooming. Flank marking was significantly inhibited in animals treated with fluoxetine or clomipramine but unaffected by treatment with desipramine. Grooming behavior was not affected by any treatment. Conclusion: These data suggest that arginine vasopressin-induced flank marking may serve as an animal model for screening drugs used in the control of Obsessive Compulsive Disorder.
引用
收藏
页数:5
相关论文
共 39 条
[1]  
ALBERS HE, 1986, J NEUROSCI, V6, P2085
[2]   BEHAVIORAL-EFFECTS OF VASOPRESSIN AND OXYTOCIN WITHIN THE MEDIAL PREOPTIC AREA OF THE GOLDEN-HAMSTER [J].
ALBERS, HE ;
FERRIS, CF .
REGULATORY PEPTIDES, 1985, 12 (03) :257-260
[3]   Effects of serotonergic agents on food-restriction-induced hyperactivity [J].
Altemus, M ;
Glowa, JR ;
Galliven, E ;
Leong, YM ;
Murphy, DL .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1996, 53 (01) :123-131
[4]   CHRONIC FLUOXETINE TREATMENT REDUCES HYPOTHALAMIC VASOPRESSIN SECRETION INVITRO [J].
ALTEMUS, M ;
CIZZA, G ;
GOLD, PW .
BRAIN RESEARCH, 1992, 593 (02) :311-313
[5]  
ALTEMUS M, 1992, ARCH GEN PSYCHIAT, V49, P9
[6]  
BLIER P, 1987, J CLIN PSYCHOPHARM, V7, pS24
[7]   A COMPARISON OF GROOMING BEHAVIOR POTENCIES OF NEUROHYPOPHYSEAL NONAPEPTIDES [J].
CALDWELL, JD ;
DRAGO, F ;
PRANGE, AJ ;
PEDERSEN, CA .
REGULATORY PEPTIDES, 1986, 14 (03) :261-271
[8]  
COOPER KE, 1979, J PHYSIOL-LONDON, V205, P33
[9]   BEHAVIORAL-RESPONSES TO INTRACEREBROVENTRICULARLY ADMINISTERED NEUROHYPOPHYSEAL PEPTIDES IN MICE [J].
DELANOY, RL ;
DUNN, AJ ;
TINTNER, R .
HORMONES AND BEHAVIOR, 1978, 11 (03) :348-362
[10]   PLASMA AND CEREBROSPINAL-FLUID MEASURES OF ARGININE VASOPRESSIN SECRETION IN PATIENTS WITH BULIMIA-NERVOSA AND IN HEALTHY-SUBJECTS [J].
DEMITRACK, MA ;
KALOGERAS, KT ;
ALTEMUS, M ;
PIGOTT, TA ;
LISTWAK, SJ ;
GOLD, PW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (06) :1277-1283